Table 4.
Results of Wilcoxon rank-sum test: median MPR for innovator brand medicines and generic medicines
| Year | Innovator brand medicines (n = 16) | Generic medicines (n = 16) | MPRIB | P | ||
|---|---|---|---|---|---|---|
| MPR | Product specific ΔMPR | MPR | Product specific ΔMPR | MPRG | ||
| 2011 | 29.51 | 8.06 | 3.66 | 0.000 | ||
| 2012 | 33.07 | 2.11 | 8.28 | −0.02 | 3.99 | 0.000 |
| 2013 | 37.20 | 2.15 | 7.18 | 0.12 | 5.18 | 0.000 |
| 2014 | 36.57 | −0.80* | 7.05 | −0.14* | 5.19 | 0.000 |
| 2015 | 28.07 | −0.85* | 5.77 | −0.16* | 4.86 | 0.002 |
| 2016 | 34.76 | −0.85 | 5.50 | −0.08 | 6.32 | 0.000 |
*P < 0.05
MPRIB MPR of innovator brand medicines, MPRG MPR of generic medicines
Product specific Δ MPR: first calculated the differences of MPR of each product between adjacent years and then chose the median value of these differences as Product specific Δ MPR